TARS Key Statistics, Chart & Performance
The current stock price of TARS is 79.44 USD. In the past month the price increased by 13.83%. In the past year, price increased by 53.39%.
TARS Latest News, Press Relases and Analysis
TARS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.57 | 988.98B | ||
| JNJ | JOHNSON & JOHNSON | 19.79 | 494.92B | ||
| MRK | MERCK & CO. INC. | 11.47 | 250.76B | ||
| PFE | PFIZER INC | 7.86 | 143.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.36 | 98.22B | ||
| ZTS | ZOETIS INC | 19.63 | 54.84B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.82B | ||
| VTRS | VIATRIS INC | 4.6 | 12.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.43 | 11.17B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.77 | 8.50B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.16B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.26B |
Related stock screener links
About TARS
Company Profile
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 323 full-time employees. The company went IPO on 2020-10-16. The firm is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The firm is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
Company Info
TARSUS PHARMACEUTICALS INC
15440 Laguna Canyon Road
Irvine CALIFORNIA 92618 US
CEO: Bobak Azamian
Employees: 323
Phone: 19494099820
TARSUS PHARMACEUTICALS INC / TARS FAQ
Can you describe the business of TARSUS PHARMACEUTICALS INC?
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. The company is headquartered in Irvine, California and currently employs 323 full-time employees. The company went IPO on 2020-10-16. The firm is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The firm is investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
What is the stock price of TARSUS PHARMACEUTICALS INC today?
The current stock price of TARS is 79.44 USD. The price decreased by -0.66% in the last trading session.
What is the dividend status of TARSUS PHARMACEUTICALS INC?
TARS does not pay a dividend.
What is the ChartMill technical and fundamental rating of TARS stock?
TARS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of TARSUS PHARMACEUTICALS INC (TARS) based on its PE ratio?
TARSUS PHARMACEUTICALS INC (TARS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.02).
What is the employee count for TARS stock?
TARSUS PHARMACEUTICALS INC (TARS) currently has 323 employees.
TARS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to TARS. When comparing the yearly performance of all stocks, TARS is one of the better performing stocks in the market, outperforming 93.28% of all stocks.
TARS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to TARS. TARS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TARS Financial Highlights
Over the last trailing twelve months TARS reported a non-GAAP Earnings per Share(EPS) of -2.02. The EPS increased by 46.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.18% | ||
| ROE | -24.22% | ||
| Debt/Equity | 0.22 |
TARS Forecast & Estimates
14 analysts have analysed TARS and the average price target is 84.81 USD. This implies a price increase of 6.75% is expected in the next year compared to the current price of 79.44.
For the next year, analysts expect an EPS growth of 48.35% and a revenue growth 145.72% for TARS